Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
François Raffi, Chloe Orkin, Amanda Clarke, et al.
The Lancet. HIV
|
October 22, 2016
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial
Aditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, et al.
The Lancet. HIV
|
July 14, 2023
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
Onyema Ogbuagu, Sorana Segal-Maurer, Winai Ratanasuwan, et al.
The Journal of Infectious Diseases
|
March 28, 2013
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results
Joel E Gallant, Ellen Koenig, Jaime Andrade-Villanueva, et al.
The Pediatric Infectious Disease Journal
|
February 4, 2012
A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents
Marinella Della Negra, Aroldo Prohmann de Carvalho, Maria Zilda de Aquino, et al.
The Lancet. HIV
|
April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Joel E Gallant, Eric S Daar, François Raffi, et al.
The Lancet. HIV
|
December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Samir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.
The Lancet. HIV
|
February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
Alan Winston, Frank A Post, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 29, 2024
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial
Onyema Ogbuagu, Jean-Michel Molina, Ploenchan Chetchotisakd, et al.
AIDS (London, England)
|
October 7, 2025
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study
Debbie Hagins, Mezgebe Berhe, Gordon E Crofoot, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
François Raffi, Chloe Orkin, Amanda Clarke, et al.
The Lancet. HIV
|
October 22, 2016
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial
Aditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, et al.
The Lancet. HIV
|
July 14, 2023
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
Onyema Ogbuagu, Sorana Segal-Maurer, Winai Ratanasuwan, et al.
The Journal of Infectious Diseases
|
March 28, 2013
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results
Joel E Gallant, Ellen Koenig, Jaime Andrade-Villanueva, et al.
The Pediatric Infectious Disease Journal
|
February 4, 2012
A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents
Marinella Della Negra, Aroldo Prohmann de Carvalho, Maria Zilda de Aquino, et al.
The Lancet. HIV
|
April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Joel E Gallant, Eric S Daar, François Raffi, et al.
The Lancet. HIV
|
December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Samir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.
The Lancet. HIV
|
February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
Alan Winston, Frank A Post, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 29, 2024
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial
Onyema Ogbuagu, Jean-Michel Molina, Ploenchan Chetchotisakd, et al.
AIDS (London, England)
|
October 7, 2025
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study
Debbie Hagins, Mezgebe Berhe, Gordon E Crofoot, et al.
Page
of 4